SK Biopharmaceuticals Co., Ltd. (326030.KS)
KRW 103600.0
(-2.54%)
KRW 103600.0
(-2.54%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 354.89 Billion | 246.17 Billion | 418.64 Billion | 25.99 Billion | 123.85 Billion | 1.09 Billion |
| Cost of Revenue | 46.51 Billion | 37.76 Billion | 22.33 Billion | 1.97 Billion | 514.19 Million | 3.34 Billion |
| Gross Profit | 308.37 Billion | 208.41 Billion | 396.3 Billion | 24.02 Billion | 123.33 Billion | -2.24 Billion |
| Operating Expenses | 358.33 Billion | 339.48 Billion | 301.35 Billion | 263.52 Billion | 202.59 Billion | 140.2 Billion |
| Selling, General and Administrative Expenses | 204.31 Billion | 112.32 Billion | 89.8 Billion | 79.09 Billion | 9.55 Billion | 9.17 Billion |
| Research and Development Expenses | 137.12 Billion | 122.81 Billion | 114.52 Billion | 108.44 Billion | 176.21 Billion | 121.28 Billion |
| Other Expenses | - | 104.35 Billion | 97.02 Billion | 75.98 Billion | 16.82 Billion | 380.48 Million |
| Cost and Expenses | 392.41 Billion | 377.25 Billion | 323.68 Billion | 265.49 Billion | 203.11 Billion | 140.2 Billion |
| Operating Income | -37.52 Billion | -131.07 Billion | 74.24 Billion | -239.49 Billion | -79.25 Billion | -139.1 Billion |
| Interest Expense | 8.27 Billion | 3.71 Billion | 946.98 Million | 4.46 Billion | 1.54 Billion | 31.49 Million |
| Income Tax Expense | -8.47 Billion | -3.03 Billion | 6.43 Billion | 7.5 Billion | -12.93 Billion | 583.19 Million |
| Earnings before Tax | -43.85 Billion | -142.46 Billion | 71.27 Billion | -239.9 Billion | -84.45 Billion | -137.63 Billion |
| Net Income | -32.88 Billion | -139.43 Billion | 64.84 Billion | -247.41 Billion | -71.51 Billion | -138.09 Billion |
| Earnings Per Share Basic | -419.89 | -1780.43 | 828.03 | -3447.52 | -3652.99 | -2219.00 |
| Earnings Per Share Diluted | -419.89 | -1780.43 | 828.03 | -3447.52 | -3652.99 | -2219.00 |
| Weighted Average Shares Outstanding | 78.31 Million | 78.31 Million | 78.31 Million | 71.76 Million | 19.57 Million | 62.23 Million |
| Weighted Average Shares Outstanding (Diluted) | 78.31 Million | 78.31 Million | 78.31 Million | 71.76 Million | 19.57 Million | 62.23 Million |
| Gross Margin | 0.87 | 0.85 | 0.95 | 0.92 | 1.00 | -2.04 |
| EBIT Margin | -0.06 | -0.46 | 0.21 | -8.71 | -0.60 | -121.81 |
| Profit Margin | -0.09 | -0.57 | 0.15 | -9.52 | -0.58 | -125.69 |
| EBITDA | -22.2 Billion | -125.76 Billion | 106.6 Billion | -224.58 Billion | -73.98 Billion | -134.26 Billion |
| Earnings Before Tax Margin | -0.11 | -0.53 | 0.18 | -9.21 | -0.64 | -126.60 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 133.99 Billion | 113.97 Billion | 126.75 Billion | 354.89 Billion | 90.33 Billion | 77.01 Billion |
| Cost of Revenue | 11.89 Billion | 15.13 Billion | 17.29 Billion | 46.51 Billion | 6.79 Billion | 9.37 Billion |
| Gross Profit | 122.09 Billion | 98.83 Billion | 109.45 Billion | 308.37 Billion | 83.54 Billion | 67.63 Billion |
| Operating Expenses | 96.05 Billion | 88.58 Billion | 94.67 Billion | 345.89 Billion | -94.25 Billion | -86.57 Billion |
| Selling, General and Administrative Expenses | 51.32 Billion | 51.2 Billion | 55.06 Billion | - | 94.25 Billion | 86.57 Billion |
| Research and Development Expenses | 43.55 Billion | 35.67 Billion | 38.63 Billion | - | 38.76 Billion | 31.47 Billion |
| Other Expenses | -1.17 Billion | -1.69 Billion | -977.66 Million | -4.45 Billion | -188.5 Billion | -173.15 Billion |
| Cost and Expenses | 107.94 Billion | 103.71 Billion | 111.97 Billion | 392.41 Billion | 6.79 Billion | 9.37 Billion |
| Operating Income | 26.04 Billion | 10.25 Billion | 14.78 Billion | -37.52 Billion | -10.71 Billion | -18.93 Billion |
| Interest Expense | - | 2.29 Billion | 2.39 Billion | 8.27 Billion | 2.25 Billion | 1.83 Billion |
| Income Tax Expense | -762.53 Million | -1.93 Billion | -5.23 Billion | -8.47 Billion | -1.41 Billion | -1.71 Billion |
| Earnings before Tax | 29.43 Billion | 13.22 Billion | 13.55 Billion | -32.32 Billion | -19.82 Billion | -25.05 Billion |
| Net Income | 28.13 Billion | 12.83 Billion | 6.75 Billion | -32.88 Billion | -13.93 Billion | -23.34 Billion |
| Earnings Per Share Basic | 359.27 | 163.86 | 86.32 | - | -177.90 | -298.06 |
| Earnings Per Share Diluted | 359.27 | 163.86 | 86.32 | - | -177.90 | -298.06 |
| Weighted Average Shares Outstanding | 78.31 Million | 78.31 Million | 78.31 Million | 78.31 Million | 78.31 Million | 78.31 Million |
| Weighted Average Shares Outstanding (Diluted) | 78.31 Million | 78.31 Million | 78.31 Million | 78.31 Million | 78.31 Million | 78.31 Million |
| Gross Margin | 0.91 | 0.87 | 0.86 | 0.87 | 0.92 | 0.88 |
| EBIT Margin | 0.23 | 0.13 | 0.15 | - | 0.92 | 0.88 |
| Profit Margin | 0.21 | 0.11 | 0.05 | -0.09 | -0.15 | -0.30 |
| EBITDA | 30.37 Billion | 14.62 Billion | 19.27 Billion | - | 83.54 Billion | 67.63 Billion |
| Earnings Before Tax Margin | 0.19 | 0.09 | 0.12 | -0.11 | -0.12 | -0.25 |
VTOL
CRE
1587
601099
214330
GGAMF